- Home
- HCM vs NAD Comparison
HCM vs NAD Comparison
Compare HCM & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCM | NAD |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | HCM | NAD |
|---|---|---|
| Price | $13.72 | $10.62 |
| Analyst Decision | Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.75 | N/A |
| AVG Volume (30 Days) | 77.2K | ★ 928.3K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.60 | N/A |
| Revenue Next Year | $15.62 | N/A |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $10.65 |
| 52 Week High | $16.99 | $12.31 |
Technical Indicators
Market Signals| Indicator | HCM | NAD |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 24.48 |
| Support Level | $12.94 | N/A |
| Resistance Level | $15.43 | $11.92 |
| Average True Range (ATR) | 0.32 | 0.15 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 75.76 | 1.33 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.